Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

Click here to select your areas of interest

Areas of interest

Select to filter on program types

E-learnings 21/01/2020

Soon to be on demand: Advanced melanoma

Over the last decade, the treatment of advanced melanoma has been significantly changed with the development of targeted and immunotherapy. Now, there is finally five-year survival data for both kinds of treatments. How do these results impact daily clinical practice? On January 21st from 20:30 until 21:30 MEDtalks broadcasts a unique e-learning, live from a studio in Brussels, wherein an expert panel led by prof. dr. Bart Neyns will discuss first- and second-line treatment of advanced melanoma with immuno and targeted therapy in patients with or without poor prognostic factors. Furthermore, the burning question on everybody’s mind after the presentation of the five-year survival results of the CheckMate 067 trial will of course not be left untouched: should patients be treated with combination immunotherapy or monotherapy? This programme will be available as an on-demand e-learning shortly afterwards. If you watch this live broadcast, you will be in the unique position to ask questions to the experts. Panel members Prof. Bart Neyns, MD, PhD, medical oncologist, University Hospital of Brussels Prof. Vibeke Kruse, MD, PhD, medical oncologist, Ghent University Hospital Annemie Rutten, MD, PhD, medical oncologist, GZA Hospital Sint-Augustinus, Antwerp Prof. Dirk van Gestel, MD, PhD, radiation oncologist, Institut Jules Bordet Subjects (among others) Five-year survival rate for immune and targeted therapy; First and second-line treatment of advanced melanoma; Combination immunotherapy versus monotherapy antiPD1 followed by anti-CTLA4; Management of patients with poor prognostic factors (e.g. brain metastases); Accreditation For this e-learning, accreditation will be arranged for medical oncologists in both Belgium and the Netherlands. Target audience Primary: Medical oncologists Secondary: Radiotherapists, dermatologists, neurosurgeons and pathologists